Print | Email Page

AbbVie successfully defends HUMIRA formulation patent against four IPR petitions filed by Coherus

September 2017

Jones Day is serving as lead counsel and successfully defended AbbVie in connection with four (4) separate inter partes review (IPR) petitions brought by Coherus Biosciences, Inc. against U.S. Patent No. 9,085,619, which is related to formulations for AbbVie's antibody adalimumab, marketed as HUMIRA®. Coherus is developing a biosimilar version of HUMIRA®. Following the filing of the Patent Owner's Preliminary Responses by AbbVie, the PTAB denied institution of each of Coherus' IPR petitions with regard to all of the challenged claims.

Coherus, Inc. v. AbbVie Biotechnology, Inc., IPR2017-00822, -00823, -01008, -01009 (PTAB)

For additional information about this matter, please contact: Anthony M. Insogna, Tamera M. Weisser Ph.D., David M. Maiorana

Client(s): AbbVie Inc.